Genetic Assay for Polycythemia Vera Prognosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for predicting the transformation of Polycythemia Vera (PV) from an indolent to an aggressive form lack effective clinical criteria and molecular markers, leading to inadequate risk stratification and increased toxicity with existing treatments.

Innovation Solution

A genetic assay measuring specific messenger RNAs (mRNAs) in blood cells, including PCNA, IFI30, TSN, CTSA, SMC4, CDKN1A, CTTN, SON, TIA1, and MYL9, to calculate a predictive score indicating the likelihood of PV transformation using an algorithm.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If gene expression profiling is used to stratify PV patients, then measurement precision of disease risk is improved, but device complexity and assay complexity increase

Engineering Contradiction:

Improvedisease risk prediction accuracyVSAvoidassay complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The complex gene expression profiling assay is segmented into a focused panel of 10 specific genes (PCNA, IFI30, TSN, CTSA, SMC4, CDKN1A, CTTN, SON, TIA1, MYL9) that are most predictive of disease transformation. This segmentation maintains measurement precision while reducing overall assay complexity by eliminating less relevant genes from the analysis.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention extracts and isolates the most critical prognostic information from the full gene expression profile by focusing specifically on 10 key genes whose expression patterns most strongly correlate with disease transformation. This extraction process captures the essential predictive signal while removing extraneous complexity from the assay.

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If early definitive therapy is instituted based on assay results, then reliability of disease management is improved, but loss of time for treatment decision increases

Engineering Contradiction:

Improvedisease management reliabilityVSAvoidtreatment decision time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The assay performs preliminary action by identifying high-risk patients before clinical transformation occurs, using the 10-gene expression profile to predict disease progression in advance. This allows clinicians to initiate definitive therapy proactively based on molecular risk stratification rather than waiting for clinical symptoms to manifest, improving reliability while actually reducing decision time through early detection.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The assay provides feedback through a quantifiable risk score based on gene expression patterns, giving clinicians objective data to guide treatment decisions. This feedback mechanism transforms complex molecular information into actionable clinical insights, improving disease management reliability while streamlining the decision-making process.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS10106855B2Genetic assay to determine prognosis in Polycythemia Vera patients

Publication Date: 2018.10.23 JOHNS HOPKINS UNIVERSITY

AI summary

The presently disclosed subject matter provides a genetic assay to determine the prognosis in Polycythemia Vera (PV) patients with an indolent form of PV. This assay involves measuring certain messenger RNAs (mRNAs) in blood cells, such as white blood cells. In some embodiments, the cells are CD34+ cells. These mRNA levels are inserted into an algorithm that yields a predictive score of the risk of PV in the patient transforming from an indolent form to an aggressive form.